This Phase 1 study tests a new T cell therapy in patients aged 12–75 with relapsed or treatment-resistant CD30-positive lymphomas.
Description
Some types of lymphoma have a marker called CD30 on the surface of cancer cells. This study explores a new treatment using CD30 CAR T cells, which are immune cells that are genetically modified to better recognize and destroy lymphoma cells. Unlike earlier approaches that used a patient’s own cells, this therapy uses T cells from healthy donors, which are stored and ready for use. These donor cells are engineered with a molecule called C7R to help them survive longer and fight cancer more effectively. The treatment also includes a safety switch (called iC9) that allows doctors to remove the cells if serious side effects occur. This study builds on previous research showing promising results with CD30 CAR T cells. It aims to test safety, determine the best dose, and monitor how long the modified cells stay active in the body. Patients may receive additional infusions if their disease stabilizes or improves.
Eligibility
Ages 12 to 75
Diagnosis of CD30-positive relapsed or refractory lymphoma, including Hodgkin lymphoma, NK or T cell lymphoma, or diffuse large B cell lymphoma (DLBCL)
Adequate organ function
Karnofsky/Lansky score ≥ 60
Detailed inclusion and exclusion criteria are listed at clinicaltrials.gov.
To inquire about this trial, fill out our online referral form:
